{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:04:47Z","timestamp":1792173887130,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89578-w","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T11:29:01Z","timestamp":1743506941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prediction of deep remission through serum TNF-\u03b1 level at 1 year of treatment in pediatric Crohn\u2019s disease"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6433-0242","authenticated-orcid":false,"given":"Seon Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5600-2070","authenticated-orcid":false,"given":"Yiyoung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2012-9867","authenticated-orcid":false,"given":"Eun Sil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1568-3364","authenticated-orcid":false,"given":"Yoon Zi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-5522","authenticated-orcid":false,"given":"Hansol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1525-7688","authenticated-orcid":false,"given":"Yon Ho","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4505-4083","authenticated-orcid":false,"given":"Mi Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"89578_CR1","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang, J. T. Pathophysiology of inflammatory bowel diseases. N Engl. J. Med. 383, 2652\u20132664 (2020).","journal-title":"N Engl. J. Med."},{"key":"89578_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","volume":"162","author":"ME Kuenzig","year":"2022","unstructured":"kuenzig, m. e. et al. twenty-first Century trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic review. Gastroenterology 162, 1147\u20131159 (2022). e4.","journal-title":"Gastroenterology"},{"key":"89578_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/MIB.0000000000000955","volume":"23","author":"MC Choy","year":"2017","unstructured":"Choy, M. C., Visvanathan, K. & De Cruz, P. An overview of the innate and adaptive immune system in inflammatory bowel disease. Inflamm. Bowel Dis. 23, 2\u201313 (2017).","journal-title":"Inflamm. Bowel Dis."},{"key":"89578_CR4","doi-asserted-by":"crossref","unstructured":"Javer, P. G. & Chaparro, M. Clinical usefulness of proteomics in inflammatory bowel disease: A comprehensive review. J. Crohns Colitis ; (2019). 13;374\u2009\u2013\u200984.","DOI":"10.1093\/ecco-jcc\/jjy158"},{"key":"89578_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clim.2018.03.004","volume":"206","author":"KH Katsanos","year":"2019","unstructured":"Katsanos, K. H., Papamichael, K., Feuerstein, J. D., Christodoulou, D. K. & Cheifetz, A. S. Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. Clin. Immunol. 206, 9\u201314 (2019).","journal-title":"Clin. Immunol."},{"key":"89578_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","volume":"20","author":"B Verstockt","year":"2023","unstructured":"Verstockt, B. et al. Alimentiv Translational Research C. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 20, 433\u2013446 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"89578_CR7","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.3390\/biomedicines10102372","volume":"10","author":"Y Kwon","year":"2022","unstructured":"Kwon, Y., Kim, E. S., Kim, Y. Z., Choe, Y. H. & Kim, M. J. Cytokine Profile at diagnosis affecting trough concentration of Infliximab in Pediatric Crohn\u2019s Disease. Biomedicines 10, 2372 (2022).","journal-title":"Biomedicines"},{"key":"89578_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00384-018-3069-8","volume":"33","author":"S Nikolaus","year":"2018","unstructured":"Nikolaus, S. et al. Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases. Int. J. Colorectal Dis. 33, 927\u2013936 (2018).","journal-title":"Int. J. Colorectal Dis."},{"key":"89578_CR9","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.clinbiochem.2008.04.021","volume":"41","author":"MA Meuwis","year":"2008","unstructured":"Meuwis, M. A. et al. Proteomics for prediction and characterization of response to infliximab in Crohn\u2019s disease: A pilot study. Clin. Biochem. 41, 960\u2013967 (2008).","journal-title":"Clin. Biochem."},{"key":"89578_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri3661","volume":"14","author":"MF Neurath","year":"2014","unstructured":"Neurath, M. F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14, 329\u2013342 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"89578_CR11","doi-asserted-by":"publisher","first-page":"eabq4473","DOI":"10.1126\/scitranslmed.abq4473","volume":"14","author":"MF Neurath","year":"2022","unstructured":"Neurath, M. F. Targeting cytokines in inflammatory bowel disease. Sci. Transl Med. 14, eabq4473 (2022).","journal-title":"Sci. Transl Med."},{"key":"89578_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01008-6","author":"MF Neurath","year":"2024","unstructured":"Neurath, M. F. Strategies for targeting cytokines in inflammatory bowel disease. Nat. Rev. Immunol. https:\/\/doi.org\/10.1038\/s41577-024-01008-6 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"89578_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.MPG.0000163736.30261.82","volume":"41","author":"IBD Working Group of the European Society for Paediatric Gastroenterology","year":"2005","unstructured":"IBD Working Group of the European Society for Paediatric Gastroenterology. Hepatology, Nutrition. Inflammatory bowel disease in children and adolescents: Recommendations for diagnosis\u2013the Porto criteria. J. Pediatr. Gastroenterol. Nutr. 41, 1\u20137 (2005).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"89578_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5009\/gnl16041","volume":"11","author":"SY Choi","year":"2017","unstructured":"Choi, S. Y., Kang, B., Lee, J. H. & Choe, Y. H. Clinical use of measuring trough levels and antibodies against Infliximab in patients with pediatric inflammatory bowel disease. Gut Liver. 11, 55\u201361 (2017).","journal-title":"Gut Liver"},{"key":"89578_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11894-013-0315-7","volume":"15","author":"C Zallot","year":"2013","unstructured":"Zallot, C. & Peyrin-Biroulet, L. Deep remission in inflammatory bowel disease: Looking beyond symptoms. Curr. Gastroenterol. Rep. 15, 315 (2013).","journal-title":"Curr. Gastroenterol. Rep."},{"key":"89578_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno, M. et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: The SES-CD. Gastrointest. Endosc 60, 505\u2013512 (2004).","journal-title":"Gastrointest. Endosc"},{"key":"89578_CR17","first-page":"A173","volume":"132","author":"DN Moskovitz","year":"2007","unstructured":"Moskovitz, D. N. et al. Defining and validating cut-offs for the simple endoscopic score for Crohn\u2019s disease. Gastroenterology 132, A173 (2007).","journal-title":"Gastroenterology"},{"key":"89578_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S2468-1253(21)00096-0","volume":"6","author":"S Geyl","year":"2021","unstructured":"Geyl, S. et al. Transmural healing as a therapeutic goal in Crohn\u2019s disease: A systematic review. Lancet Gastroenterol. Hepatol. 6, 659\u2013667 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"89578_CR19","unstructured":"Immunodiagnostik, A. G. IDKmonitor\u00ae Infliximab drug level ELISA. (2023). https:\/\/www.immundiagnostik.com\/media\/pages\/testkits\/k-9655\/\/f203b58fa6-1716973065\/k9655_2023-11-23.pdf. Accessed 6 June 2024."},{"key":"89578_CR20","unstructured":"Immunodiagnostik, A. G. IDKmonitor\u00ae Infliximab free ADA ELISA. (2024). https:\/\/www.immundiagnostik.com\/media\/pages\/testkits\/k-9650\/6f4ec0da0b-1716973070\/k9650_2024-02-26_idkmonitor_infliximab_ada.pdf. Accessed 6 June 2024."},{"key":"89578_CR21","doi-asserted-by":"publisher","first-page":"175628482311709","DOI":"10.1177\/17562848231170948","volume":"16","author":"ES Kim","year":"2023","unstructured":"Kim, E. S., Kwon, Y., Choe, Y. H. & Kim, M. J. Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn\u2019s disease patients with secondary loss of response. Th. Adv. Gastroenterol. 16, 17562848231170948 (2023).","journal-title":"Th. Adv. Gastroenterol."},{"key":"89578_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/FTD.0000000000000404","volume":"39","author":"K Bloem","year":"2017","unstructured":"Bloem, K., Hernandez-Breijo, B., Martinez-Feito, A. & Rispens, T. Immunogenicity of therapeutic antibodies: Monitoring antidrug antibodies in a clinical context. Ther. Drug Monit. 39, 327\u2013332 (2017).","journal-title":"Ther. Drug Monit."},{"key":"89578_CR23","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1046\/j.1365-2036.2001.01093.x","volume":"15","author":"JO Lindsay","year":"2001","unstructured":"Lindsay, J. O. & Hodgson, H. J. Review article: the immunoregulatory cytokine interleukin-10\u2013a therapy for Crohn\u2019s disease? Aliment. Pharmacol. Ther. 15, 1709\u20131716 (2001).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"89578_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","volume":"29","author":"W Ouyang","year":"2011","unstructured":"Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A. & Hymowitz, S. G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29, 71\u2013109 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"89578_CR25","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.immuni.2014.03.011","volume":"40","author":"DS Shouval","year":"2014","unstructured":"Shouval, D. S. et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity 40, 706\u2013719 (2014).","journal-title":"Immunity"},{"key":"89578_CR26","doi-asserted-by":"publisher","first-page":"26875","DOI":"10.1155\/MI\/2006\/26875","volume":"2006","author":"K Mitsuyama","year":"2006","unstructured":"Mitsuyama, K. et al. Interleukin-10 in the pathophysiology of inflammatory bowel disease: Increased serum concentrations during the recovery phase. Mediators Inflamm. 2006, 26875 (2006).","journal-title":"Mediators Inflamm."},{"key":"89578_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clim.2017.08.023","volume":"187","author":"SK Bedri","year":"2018","unstructured":"Bedri, S. K. et al. Multiple sclerosis treatment effects on plasma cytokine receptor levels. Clin. Immunol. 187, 15\u201325 (2018).","journal-title":"Clin. Immunol."},{"key":"89578_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/nyas.12821","volume":"1351","author":"K Janssens","year":"2015","unstructured":"Janssens, K., Slaets, H. & Hellings, N. Immunomodulatory properties of the IL-6 cytokine family in multiple sclerosis. Ann. N Y Acad. Sci. 1351, 52\u201360 (2015).","journal-title":"Ann. N Y Acad. Sci."},{"key":"89578_CR29","doi-asserted-by":"publisher","first-page":"105435","DOI":"10.1016\/j.msard.2024.105435","volume":"83","author":"B Yamout","year":"2024","unstructured":"Yamout, B. et al. Consensus recommendations for diagnosis and treatment of multiple sclerosis: 2023 revision of the MENACTRIMS guidelines. Mult Scler. Relat. Disord. 83, 105435 (2024).","journal-title":"Mult Scler. Relat. Disord"},{"key":"89578_CR30","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3109\/00365521.2015.1027264","volume":"50","author":"DR Hoekman","year":"2015","unstructured":"Hoekman, D. R. et al. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease. Scand. J. Gastroenterol. 50, 1110\u20131117 (2015).","journal-title":"Scand. J. Gastroenterol."},{"key":"89578_CR31","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1093\/ibd\/izy132","volume":"24","author":"K Papamichael","year":"2018","unstructured":"Papamichael, K., Rakowsky, S., Rivera, C., Cheifetz, A. S. & Osterman, M. T. Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn\u2019s disease. Inflamm. Bowel Dis. 24, 2266\u20132271 (2018).","journal-title":"Inflamm. Bowel Dis."},{"key":"89578_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa161","author":"PF van Rheenen","year":"2020","unstructured":"van Rheenen, P. F. et al. The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update. J. Crohns Colitis. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa161 (2020).","journal-title":"J. Crohns Colitis"},{"key":"89578_CR33","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1111\/apa.14008","volume":"106","author":"V Deora","year":"2017","unstructured":"Deora, V., Kozak, J., El-Kalla, M., Huynh, H. Q. & El-Matary, W. Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease. Acta Paediatr. 106, 1863\u20131867 (2017).","journal-title":"Acta Paediatr."},{"key":"89578_CR34","doi-asserted-by":"crossref","unstructured":"Nguyen, N. H. et al. Proactive therapeutic drug monitoring Versus Conventional Management for Inflammatory Bowel diseases: A systematic review and Meta-analysis. Gastroenterology 163 937\u2009\u2013\u200949 e2. (2022)","DOI":"10.1053\/j.gastro.2022.06.052"},{"key":"89578_CR35","first-page":"211","volume":"10","author":"N Avdagi\u0107","year":"2013","unstructured":"Avdagi\u0107, N. et al. Tumor necrosis factor-alpha serum level in assessment of disease activity in inflammatory bowel diseases. Med. Glas (Zenica) 10, 211\u2013216 (2013).","journal-title":"Med. Glas (Zenica)"},{"key":"89578_CR36","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/gut.32.8.913","volume":"32","author":"SH Murch","year":"1991","unstructured":"Murch, S. H., Lmkin, V. A., Savage, M. O., Walker-Smith, J. A. & MacDonald, T. T. Serum concentrations of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32, 913\u2013917 (1991).","journal-title":"Gut"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89578-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89578-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89578-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T11:29:27Z","timestamp":1743506967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89578-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89578"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89578-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Clinical Research Ethics Committee approved the review of patient medical records, and appropriate written consent procedures were undertaken for laboratory tests and imaging studies. Name of the ethics committee and reference: Samsung Medical Center IRB File No.: SMC 2020-04-046.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"5770"}}